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Morphology of the heart and arteries in renal failure. In pa- of the sympathetic nervous system or Ca2 overload, may
tients with renal failure, cardiovascular complications are a play a role. Furthermore, parathyroid hormone (PTH)
major clinical problem; cardiac death is the main cause of death is widely acknowledged as a permissive factor for thein these patients. Cardiac risk is increased by a factor of 20 in
development of cardiac hypertrophy, interstitial fibrosis,uremic patients, compared with matched segments of the gen-
and arteriolar alterations.eral population.
It has been known for a long time that atherosclerosis, partic- Whether atherogenesis is really accelerated in renal
ularly plaque in the epicardiac coronary conduit arteries, are failure as initially described remains a matter of debate,
more frequent in patients with chronic renal failure. Recently, but there is definitely a very high prevalence of athero-however, clinical studies showed that myocardial infarction is
sclerotic lesions with particularly heavy vascular calcifi-responsible for only 30% to 50% of all cardiac deaths. In
cation [5].contrast, 30% to 40% of patients with renal failure and ischemic
heart disease show patent coronary arteries on coronary angio- The present review shall discuss the issues of LVH,
gram. Thus, it is very likely that in uremic patients myocardial coronary heart disease, microvascular disease, cardiac
ischemia tolerance is markedly reduced even in the absence fibrosis, and extracardiac vascular alterations in renalof classical atherosclerosis (i.e., relevant stenosis of coronary
failure that compromise cardiac and vascular functionarteries). This finding in uremic patients can be at least partially
and contribute to the increased cardiovascular mortalityexplained by structural and metabolic abnormalities of the
myocardium, and in part by alterations of the extracardiac in patients with renal failure.
vasculature. The present paper focuses on structural changes
of the heart and the vasculature, in particular on atherosclerosis
of cardiac and extracardiac arteries, and its potential repercus- LEFT VENTRICULAR HYPERTROPHY (LVH)
sions for cardiovascular function.
In subtotally nephrectomized (SNX) rats and in ure-In 1827 Richard Bright already pointed to the common pres-
mic patients, a marked increase in left ventricular massence of left ventricular hypertrophy (LVH) and thickening of
the aorta in patients with end-stage renal failure (ESRF). At is seen very early in the course of renal failure. Left
present, cardiovascular complications account for 45% of all ventricular disease is already present in 85% of patients
deaths in uremic patients [1]. The recent report of Herzog,
starting dialysis. Sixteen percent of patients had systolicMa, and Colins [2] documented a 59.3% 1-year mortality rate
dysfunction, 41% concentric LVH, 28% left ventricularin dialyzed patients who survived myocardial infarction (i.e.,
mortality was significantly higher than in the general popula- dilatation, and only 16% had normal cardiac findings
tion). It is widely acknowledged that several specific structural on echocardiography. These cardiac abnormalities are
and nonstructural alterations of the heart and the extracardiac closely correlated to the development of heart failure
vasculature are present in patients with renal failure, which
and reduced patient survival. By multivariate analysis,presumably contribute to the markedly increased cardiovascu-
LVH was found to be an independent predictor of pa-lar risk in these patients [3].
tient survival. Clinically, LVH could be partially reversed
by antihypertensive treatment with angiotensin-con-
verting enzyme (ACE) inhibitors, by correction of ane-Recent clinical and experimental studies clearly docu-
mia with human recombinant erythropoietin (rhEPO),ment that the pathogenesis of cardiovascular abnormali-
and by reduction of pre- and afterload achieved by forcedties in renal failure is much more complex than initially
ultrafiltration.thought [4]. Apart from elevated blood pressure, hyper-
In experimental renal failure, LVH is associated withvolemia, anemia, activation of local endocine systems,
an increase in cardiomyocyte diameter, which leads tosuch as the renin-angiotensin system (RAS) and the en-
an increase in oxygen diffusion distance and must impededothelin (ET) system, as well as inadequate activation
diffusion of oxygen to the cardiomyocyte. Apart from
cardiomyocyte hypertrophy, the left ventricle of uremic
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ptosis during the transition to heart failure. In parallel, 2003 by the International Society of Nephrology
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the development of LVH is associated with a 40% de- tative morphologic studies have documented hypertro-
phy of vascular smooth muscle cells (VSMCs) andcrease in left ventricular contractility and increased ET-1
mRNA and protein expression. In experimental studies increased expression of the vascular endothelial growth
factor (VEGF), platelet derived growth factor (PDGF),LVH could be prevented, at least in part, by administra-
tion of ACE inhibitors, sympatholytic agents, ET-1 re- collagen IV, actin, and integrin-1. Experimental studies
have clearly documented a permissive role for PTH inceptor blockers, and rhEPO treatment.
the genesis of intramyocardial artery wall thickening;
this is consistent with clinical studies showing that PTH
CORONARY HEART DISEASE
concentrations correlate with cardiac morbidity and car-
Postmortem and coronarography studies documented diac death in dialysis patients. Treatment with ACE in-
that ischemic heart disease due to stenosis of coronary hibitors, ET-1 receptor blockers, calcium channel block-
arteries is very common in patients with renal failure. ers, high doses of vitamin E, or a low-phosphate diet
Apart from sudden death, myocardial infarction is the prevented thickening of the intramyocardial arterial wall.
most common cause of death in these patients. The prev-
alence of coronary artery stenosis varies from 24% in Cardiac capillaries
young nondiabetic hemodialysis patients to 85% in el- In addition to intramyocardial arteriolar wall thick-
derly uremic patients with type 1 diabetes. Recent ad- ening, reduction of capillary density may further inter-
vances in atherosclerotic research point to the impor- fere with myocardial blood and oxygen supply. In SNX
tance of the morphology of the atherosclerotic plaque, rats with moderate renal failure of short or long duration,
which was shown to be not a static, but rather a dynamic cardiac capillary length density (i.e., the total length of
structure undergoing permanent remodeling. Among all capillaries per volume of myocardium) is reduced
others, the balance between metalloproteinases (MMP) compared with controls (25%). Such a decrease in
and tissue inhibitors of MMP activities determines the myocardial capillary supply was not noted in other exper-
stability of the fibrous cap. Plaques covered by a thick imental models with comparable LVH. Thus, capillary
fibrous cap are stable lesions (i.e., the risk of rupture is rarefaction is specific for uremia and is not a nonspecific
relatively small). In contrast, plaques with a large lipid consequence of hypertension or LVH. The decrease in
core are unstable and entail a high risk of rupture. This capillary density leads to an increase in intercapillary
concept of plaque stability may explain why only a loose distance (i.e., the distance between the center of a myo-
correlation exists between coronary artery stenosis by cyte and the adjacent capillary) and this may further
angiography and cardiac events. It is of interest that compromise the blood and oxygen supply of cardiomyo-
in uremic patients atherosclerotic lesions are far more cytes under conditions of increased demand. These con-
advanced (i.e., more calcified) than in nonrenal patients. ditions render the myocardium more susceptible to isch-
Uremic patients also have a much higher risk of plaque emic injury. Similar observations were made in uremic
rupture, which may be due to the high density of acti- patients. Reduced cardiac capillary length density was
vated macrophages in the plaques [3, 5]. The intima noted in patients with renal failure as compared with
thickness of coronary arteries of uremic patients is also patients with essential hypertension and normotensive
increased, which is consistent with the notion of endothe- control patients. This finding implies that in LVH of
lial cell injury and repair. uremic patients, capillary growth does not keep pace
with cardiomyocyte growth, apparently because of some
selective inhibition or lacking stimulation of capillaryMICROVASCULAR DISEASE
angiogenesis.Intramyocardial arteries
In experimental renal failure, the reduction in cardiac
Previous clinical studies have documented patent cor- capillary supply could be prevented by sympatholytic
onary arteries on coronarography in up to 50% of uremic treatment, selective and non-selective ET receptor block-
patients with angina pectoris. This finding is comparable ade, as well as antioxidative therapy with vitamin E.
to what was documented in hypertensive patients with
syndrome X (i.e., angina pectoris despite patent coronary
INTERMYOCARDIOCYTE FIBROSISarteries); such patients have microangiopathy with plaques
of the small intramyocardial arteries (i.e., wall thickening Two centuries ago, Debove and Letulle were the first
to mention “that a fibrous growth between the muscularand reduced arteriolar lumen). In experimental renal
failure and in uremic patients, intramyocardial arteriolar fibers of the left ventricle is common in Bright’s disease.”
A selective increase in intermyocytic fibrotic tissue waswall thickening largely independent of blood pressure
is consistently found. This may not necessarily lead to first described by Ro¨ssle and Pirani in the 1940s. This
finding was later confirmed in short- and long-term ex-increased baseline vascular resistance, but it may inter-
fere with vasodilatation (i.e., perfusion reserve). Quanti- perimental renal failure and in uremic patients [6]. A
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selective increase in cardiac interstitial cell and nuclear
volume, but not in endothelial cell volume, was found
in association with ultrastructural signs of cell activation.
This abnormality was not seen in experimental models
of genetic and renovascular hypertension, respectively,
or in patients with essential hypertension, underlining
that this finding is specific for uremia. Interstitial fibrosis
could be prevented by ACE inhibitors, ET-1 receptor
blockade, antioxidative treatment with vitamin E and
low-phosphate diet.
Myocardial fibrosis presumably has important func-
tional consequences. Interposition of collagen fibers be-
tween cardiomyocytes and capillaries may contribute to
myocardial ischemia by causing displacement of capillar-
ies, increase in intercapillary diffusion distance, reduc-
tion of myocardial compliance, changes in the stress-
strain-relation, and electrical instability by promoting
reentrant type of arrhythmias. The latter is thought to
be due to fragmentation and local delay of the front of
the action potential by interposed collagen fibers, leading
to dispersal of the state of refractoriness and favoring
reentry tachycardia. This may explain why, in patients
with essential hypertension, cardiac fibrosis is known to
be associated with an increased risk of cardiac death due
to arrhythmias.
CHANGES OF EXTRACARDIAC ARTERIES
AND VEINS
In addition to changes in cardiac arteries, patients with
renal failure present with thickening of elastic (aorta,
carotid artery) and muscular type peripheral arteries and
peripheral veins [7]. The increase in aortic wall thickness
is primarily due to hyperplasia of VSMCs, but also to
an increase in extracellular matrix content with a con-
comitant decrease and architectural derangement of
elastic fibers (Fig. 1). Increased intima-media thickness
of the carotid artery and associated alterations of the Fig. 1. Aortic wall thickening with changes in the elastic fiber distribu-
tion in a subtotally nephrectomized rat (B) compared with a controlvessel function in patients with renal failure were shown
rat (A). Paraffin sections, immunohistochemistry.by Barenbrock et al [8]. Recently, Shoji et al [9] docu-
mented that increased intima-media thickness of carotid
arteries is already present in patients with renal failure
uremia.” Several clinical and, in particular, autopticalbefore starting hemodialysis, supporting the concept that
studies confirmed the high prevalence of cardiac andthe arterial alterations (as well as the cardiac changes)
vascular calcification in patients with renal failure andare not due to hemodialysis treatment but to renal failure
particularly in diabetic patients on dialysis [11, 12]. In aper se or associated secondary abnormalities.
recent paper, Oh et al [13] showed that atherosclerosis
is even present in very young adults with renal failure.
ATHEROSCLEROSIS OF CARDIAC AND In an autoptical study, plaque composition and size in
EXTRACARDIAC ARTERIES patients with renal failure was compared with nonrenal
The question whether atherosclerosis is more common patients. Patients with renal insufficiency exhibited more
or more aggressive in patients with renal failure than in severe lesions and a significantly higher number of STARY
matched segments of the general population is hotly type VII lesions, that is, the calcified plaque [5]. Using
debated since the seminal paper of Lindner et al [10], radiographic diffraction analysis, deposition of hydroxy-
apatite was confirmed in these calcified plaques, an ob-who postulated that “atherosclerosis is accelerated in
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